There Is More to Length of Survival Than Survival: Endpoints in Oncology Trials.
Clin Cancer Res
; 30(15): 3098-3099, 2024 Aug 01.
Article
en En
| MEDLINE
| ID: mdl-38767553
ABSTRACT
Progression-free survival as a primary endpoint for comparative trials does not fully capture the therapeutic risk/benefit ratio. Additionally, summarization of the treatment effect via a hazard ratio is problematic when the proportional hazards assumption is violated. Restricted mean survival time metrics may address these challenges but have other limitations. See related article by Chang et al., p. 3282.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Ensayos Clínicos como Asunto
/
Neoplasias
Límite:
Humans
Idioma:
En
Revista:
Clin Cancer Res
/
Clin. cancer res
/
Clinical cancer research
Asunto de la revista:
NEOPLASIAS
Año:
2024
Tipo del documento:
Article
Pais de publicación:
Estados Unidos